TY - JOUR
T1 - Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy
AU - Aguilar, David
AU - Goldhaber, Samuel Z.
AU - Gans, Daniel J.
AU - Levey, Andrew S.
AU - Porush, Jerome G.
AU - Lewis, Julia B.
AU - Rouleau, Jean Lucien
AU - Berl, Tomas
AU - Lewis, Edmund J.
AU - Pfeffer, Marc A.
N1 - Funding Information:
The Irbesartan Diabetic Nephropathy Trial was sponsored with grant support by Bristol-Myers Squibb Pharmaceutical Research Institute, Pennington, New Jersey, and Sanofi-Synthelabo, Inc., New York, New York.
PY - 2004/8/1
Y1 - 2004/8/1
N2 - During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction (MI). During a mean follow-up of 2.5 years, 14 of 99 first nonfatal MIs in this group were clinically unrecognized, accounting for 14% of all first nonfatal MIs.
AB - During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction (MI). During a mean follow-up of 2.5 years, 14 of 99 first nonfatal MIs in this group were clinically unrecognized, accounting for 14% of all first nonfatal MIs.
UR - http://www.scopus.com/inward/record.url?scp=3242705235&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3242705235&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2004.04.028
DO - 10.1016/j.amjcard.2004.04.028
M3 - Article
C2 - 15276098
AN - SCOPUS:3242705235
SN - 0002-9149
VL - 94
SP - 337
EP - 339
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 3
ER -
